Individualized Fracture Prevention for Postmenopausal Women with Osteopenia.

Area of Science:

• Gerontology
• Endocrinology
• Orthopedics

Background:

• Osteopenia, a bone mineral density T-score between -1.0 and -2.5, is more prevalent than osteoporosis.
• Approximately 50% of Korean women aged 50 years and older have osteopenia, a condition often leading to fragility fractures.
• Optimal therapeutic strategies for osteopenia remain unclear, necessitating a review of its clinical significance and management.

Purpose of the Study:

• To summarize the clinical significance of osteopenia.
• To review current management strategies for osteopenia in postmenopausal women.
• To highlight the importance of fracture risk assessment in osteopenia management.

Main Methods:

• Review of clinical practice guidelines and relevant studies on osteopenia.
• Analysis of fracture risk progression from normal bone density to osteopenia and osteoporosis.
• Examination of pharmacological interventions and risk assessment tools like FRAX®.

Main Results:

• Moderate to severe osteopenia significantly elevates fracture risks, particularly for hip and vertebral fractures.
• Around 10% of women with normal bone density or osteopenia progress to osteoporosis.
• Current evidence for medications in fracture prevention for osteopenia is limited but growing.

Conclusions:

• Treatment for fracture prevention in postmenopausal women should extend beyond osteoporosis to include moderate to severe osteopenia.
• Individualized treatment plans considering fracture risk, patient factors, and cost-effectiveness are essential.
• Pharmacological interventions approved by the FDA, such as hormone therapy and bisphosphonates, may benefit women with moderate to severe osteopenia.